FIREFLY NEUROSCIENCE, INC. (AIFF) stock: key figures, P/E, revenue and dividend
Information Technology · United States · ISIN US3179701012
FIREFLY NEUROSCIENCE, INC. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 108,000.00 USD | 1.14 m USD |
| Gross profit | 108,000.00 USD | 645,000.00 USD |
| Operating income | -10.05 m USD | -8.86 m USD |
| EBIT | -10.46 m USD | -19.97 m USD |
| Net income | -10.46 m USD | -19.88 m USD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About FIREFLY NEUROSCIENCE, INC.
Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain in North America. The company offers the Evoke System, a system used to perform electroencephalographic (EEG) and event-related potential (ERP) assessments, which are analyzed by its cloud-based platform and returned as structured reports designed to support clinical decision-making for various diseases, including depression, anxiety, ADHD, PTSD, MCI, dementia, Parkinson's disease, bipolar disorder, schizophrenia, schizoaffective disorder, ASD, and traumatic brain injury. It serves clinicians. Firefly Neuroscience, Inc. was founded in 2006 and is based in Kenmore, New York.
More stocks
- Cytosorbents Corp (CTSO)
- Pluri Inc. (PLUR)
- Bridger Aerospace Group Holdings, Inc. (BAER)
- Investcorp Credit Management BDC, Inc. (ICMB)
- Security Midwest Bancorp, Inc. (SBMW)
- American Strategic Investment Co. (NYC)
- Creative Media & Community Trust Corp (CMCT)
- Citius Pharmaceuticals, Inc. (CTXR)
- NextTrip, Inc. (NTRP)
- Marker Therapeutics, Inc. (MRKR)
- Local Bounti Corporation/DE (LOCL)
- QUOTEMEDIA INC (QMCI)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.